Donor CAR T cells targeting CD19 and CD22 to prevent relapse in adult B‑ALL
Donor Derived CD19/CD22 CAR T Cells as Concurrent Therapy Against Relapse in Adults with B-ALL
Adults with B‑cell acute lymphoblastic leukemia receive a donor stem‑cell transplant with regulatory T cells followed by donor CAR T cells that target CD19 and CD22 to try to lower the chance the leukemia comes back.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11197508 on NIH RePORTER |
What this research studies
You would receive an allogeneic stem‑cell transplant that includes purified regulatory T cells, CD34+ stem cells, and conventional T cells to help prevent graft‑versus‑host disease. After the transplant, you would get a consolidative dose of donor‑derived CAR T cells engineered to recognize both CD19 and CD22 on B cells. The project is being run as a phase I, single‑center program at Stanford and includes laboratory correlative studies and supporting preclinical work. The goal is to see whether combining Treg‑enriched grafts with donor CAR T cells can reduce relapse while keeping GVHD manageable.
Who could benefit from this research
Good fit: Ideal candidates are adults (21+) with B‑cell acute lymphoblastic leukemia who are planned for or eligible to receive an allogeneic stem‑cell transplant and meet clinical criteria for post‑transplant donor CAR T cell therapy.
Not a fit: Children, people with non‑B‑ALL cancers, those not eligible for allogeneic transplant, or individuals with uncontrolled medical issues or infections are unlikely to benefit from this specific program.
Why it matters
Potential benefit: If successful, this approach could lower relapse rates after donor transplant and help more adults with B‑ALL achieve longer remissions with controllable GVHD.
How similar studies have performed: Autologous CD19/CD22 CAR T therapies have produced remissions but many patients relapsed, and preliminary data indicate donor‑derived CAR T cells after transplant may cause less GVHD, so this combined approach is relatively new and is being tested.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Miklos, David B. — Stanford University
- Study coordinator: Miklos, David B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.